AstraZeneca officials have said two-thirds of an expected $500 million in savings from the merger with MedImmune could stem from cutting overlap between the two companies.
The brunt of that will likely hit MedImmune's sales and marketing force, which makes up about a quarter of its 1,200 local and 2,500 total employees, says Gbola Amusa, a senior research analyst at Sanford Bernstein & Co.
With MedImmune's largely flattening sales of its blockbuster Synagis drug and flailing sales of its one-time highly anticipated FluMist drug, Amusa says AstraZeneca will take sharp aim at lagging sales teams, particularly in its overlapping cancer, respiratory and infectious disease areas.
"AstraZeneca may be more likely to take out padding where people haven't been performing up to snuff," Amusa said. "Sales and marketing people could lose their jobs, almost by half."
More
No comments:
Post a Comment